John B Mumm
Overview
Explore the profile of John B Mumm including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
1078
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Naing A, Infante J, Papadopoulos K, Chan I, Shen C, Ratti N, et al.
Cancer Cell
. 2018 Nov;
34(5):775-791.e3.
PMID: 30423297
Tumor-reactive T cell exhaustion prevents the success of immune therapies. Pegilodecakin activates intratumoral CD8 T cells in mice and induces objective tumor responses in patients. Here we report that pegilodecakin...
2.
Chan I, Wu V, Bilardello M, Jorgenson B, Bal H, McCauley S, et al.
Oncoimmunology
. 2016 Sep;
5(7):e1197458.
PMID: 27622052
IL-10 has been classically defined as a broad-spectrum immunosuppressant and is thought to facilitate the development of regulatory CD4(+) T cells. IL-10 is believed to represent one of the major...
3.
Naing A, Papadopoulos K, Autio K, Ott P, Patel M, Wong D, et al.
J Clin Oncol
. 2016 Aug;
34(29):3562-3569.
PMID: 27528724
Purpose Interleukin-10 (IL-10) stimulates the expansion and cytotoxicity of tumor-infiltrating CD8+ T cells and inhibits inflammatory CD4+ T cells. Pegylation prolongs the serum concentration of IL-10 without changing the immunologic...
4.
Chan I, Van Hoof D, Abramova M, Bilardello M, Mar E, Jorgensen B, et al.
PLoS One
. 2016 Jun;
11(6):e0156229.
PMID: 27299860
Interleukin-10 (IL-10) is a multifunctional cytokine that exerts potent context specific immunostimulatory and immunosuppressive effects. We have investigated the mechanism by which PEGylated rIL-10 regulates plasma cholesterol in mice and...
5.
Chan I, Wu V, McCauley S, Grimm E, Mumm J
Receptors Clin Investig
. 2015 Dec;
2(4).
PMID: 26661378
Recent advances in immunoncology have dramatically changed the treatment options available to cancer patients. However, the fundamental challenges with this therapeutic modality are not new and still persist with the...
6.
Mumm J, Oft M
Bioessays
. 2013 May;
35(7):623-31.
PMID: 23666891
Recently, the development of several strategies based on immunotherapy has raised hopes for a more promising way to treat cancer patients. Here, we describe how interleukin (IL)-10, a seemingly unlikely...
7.
Emmerich J, Mumm J, Oft M
Oncoimmunology
. 2012 Dec;
1(9):1637-1639.
PMID: 23264920
Successful cancer immunotherapy is thought to require de novo priming of tumor specific CD8(+) T cells in lymphatic organs. Contrasting these beliefs, cancer therapy based on interleukin-10 (IL-10) results in...
8.
Mumm J, Emmerich J, Oft M
Oncoimmunology
. 2012 Dec;
1(9):1598-1600.
PMID: 23264906
Interleukin-10 (IL-10) is considered to be an immunosuppressive cytokine. However, the continuous administration of pegylated IL-10 (PEG-IL10) leads to the rejection of large, firmly established and metastatic syngeneic tumors. PEG-IL10...
9.
Emmerich J, Mumm J, Chan I, LaFace D, Truong H, Mcclanahan T, et al.
Cancer Res
. 2012 May;
72(14):3570-81.
PMID: 22581824
The presence of activated intratumoral T cells correlates clinically with better prognosis in patients with cancer. Although tumor vaccines can increase the number of tumor-specific CD8(+) T cells in systemic...
10.
Mumm J, Emmerich J, Zhang X, Chan I, Wu L, Mauze S, et al.
Cancer Cell
. 2011 Dec;
20(6):781-96.
PMID: 22172723
Tumor immune surveillance and cancer immunotherapies are thought to depend on the intratumoral infiltration of activated CD8(+) T cells. Intratumoral CD8(+) T cells are rare and lack activity. IL-10 is...